Cargando…
Impact of empagliflozin on diabetic kidney disease
Empaglifolzin reduces metabolic derangements such as BP (blood pressure), hyperglycemia, body weight, uric acid, increases Ht (hamtaocrit), keton bodies, and restores altered tubule‐glomerular feedback, thereby protect against diabetes‐induced caidio‐renal injuries.[Image: see text]
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583951/ https://www.ncbi.nlm.nih.gov/pubmed/28035769 http://dx.doi.org/10.1111/jdi.12615 |